Yahoo! Finance Search - Finance Home - Yahoo! - Help

Monday, April 21 2014 3:28am ET - U.S. Markets open in 6 hours and 2 minutes.
Industry Center - Biotechnology
Industry Center > Biotechnology > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Biotechnology News
Latest News
Sunday, Apr 20, 2014
·Verastem: Cancer May Have Met Its Match
at Seeking Alpha - Sun 2:29 pm ET
Saturday, Apr 19, 2014
·4 Reasons You Should Watch This Under-the-Radar Stock on Your Watchlist
at Motley Fool - Sat 6:32 pm ET
·1 of These 3 Cratering Biotechs is a Buy
at Motley Fool - Sat 6:31 pm ET
·Meet the Company That's Changing the Multiple Sclerosis Treatment Landscape
at Motley Fool - Sat 2:06 pm ET
·This Medical Marijuana Stock Is Not What You Think
at Motley Fool - Sat 1:32 pm ET
·3 Humongous Health-Care Stocks This Week
at Motley Fool - Sat 12:48 pm ET
·Clinical Trial Of Juno Therapeutics Cell Therapy Restarts
at Forbes.com - Sat 9:53 am ET
·Nektar Fortifies Its Position In Advance Of The Rescheduled FDA Panel On OIC
at Seeking Alpha - Sat 9:22 am ET
·[$$] A High-Profile Decision for the FDA
at Barrons.com - Sat Apr 19
Friday, Apr 18, 2014
·Dicerna Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Fri Apr 18
·Exclusive: Biogen prices hemophilia drug on par with older therapies
Reuters - Fri Apr 18
·In Case You Missed It: GlaxoSmithKline Just Had a Phenomenal Week!
at Motley Fool - Fri Apr 18
·Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear
at Motley Fool - Fri Apr 18
·Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily, Inc. - Fri Apr 18
·Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of One Lot of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Due to Presence of Particulate Matter
Business Wire - Fri Apr 18
·Cohen’s Point72 Asset Management buys a stake in MacroGenics
- Fri Apr 18
·Opportunities Among The Rubble Of The Biotech Selloff
at Forbes.com - Fri Apr 18
·Pharma-Bio 2Q14 Update: $9 Billion in Project Starts Reflects 91% Gain in Industry Capital Investment, an Industrial Info News Alert
Marketwire - Fri Apr 18
Thursday, Apr 17, 2014
·Cost of Treatment May Influence Doctors
at The New York Times - Thu Apr 17
·Xenoport's Path Is Long, But The Potential Is There
at Seeking Alpha - Thu Apr 17
More Latest News...
Sponsor Results
Shimadzu Life Science
A new way of thinking in the health and life science industries
www.ssi.shimadzu.com
Industry News & Insights
Learn more about Industry News from the CSG Newsroom.
Newsroom.ChainStoreGuide.com
Lumosity Brain Games
Train memory and attention with scientific brain games.
www.lumosity.com
(What's This?)
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Biotechnology Headlines
More Finance RSS Feeds


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?